Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia
Adult
Male
0301 basic medicine
Bone Density Conservation Agents
Diphosphonates
Osteocalcin
beta-Thalassemia
Imidazoles
Osteoprotegerin
Zoledronic Acid
Bone and Bones
Collagen Type I
03 medical and health sciences
Treatment Outcome
Bone Density
Humans
Osteoporosis
Female
Insulin-Like Growth Factor I
Peptides
Biomarkers
DOI:
10.1007/s00277-006-0180-7
Publication Date:
2006-09-29T13:37:09Z
AUTHORS (7)
ABSTRACT
Osteoporosis has emerged as an important cause of morbidity in patients with thalassemia major. Studies regarding the efficacy of bisphosphonates in thalassemia-induced osteoporosis have yielded conflicting results. We performed this prospective study to evaluate the efficacy of zoledronic acid in osteoporotic patients with thalassemia major. Patients, 29, were given 1 mg zoledronic acid intravenously every 3 months for a total of four doses. Twenty age- and sex-matched healthy blood donors served as controls. Before each infusion and 3 months after the last infusion, we determined serum levels of osteoprotegerin (OPG), N-terminal cross-linking telopeptide of type I collagen (NTX), osteocalcin (OC) and insulin-like growth factor 1 (IGF-1). Bone mineral density (BMD) of the lumbar spine was measured at baseline and after the treatment's completion. At baseline, OPG did not differ significantly between patients and controls (p=0.2), NTX were higher in patients although not significantly (p=0.139), whereas, OC levels were significantly higher and IGF-1 levels significantly lower in patients than in controls (p<0.001 and p<0.006, respectively). Zoledronic acid administration resulted in a significant decrease in NTX, OC and IGF-1 (p<0.05, p<0.001 and p<0.05, respectively) and in a significant increase in OPG and BMD (p<0.05 for both comparisons). The change in NTX, osteocalcin and IGF-1 became significant as early as 3 months after the first administration of zoledronic acid, while the change in OPG reached significance only after three infusions. Our study supports the effectiveness of bisphosphonates in the treatment of thalassemia-induced osteoporosis.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (59)
CITATIONS (23)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....